|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in china,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jayachandran A, Dhungel B and Steel JC:
Epithelial-to-mesenchymal plasticity of cancer stem cells:
Therapeutic targets in hepatocellular carcinoma. J Hematol Oncol.
9:742016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Etik Ozer D, Suna N and Boyacioglu AS:
Management of hepatocellular carcinoma: Prevention, surveillance,
diagnosis, and staging. Exp Clin Transplant. 15:31–35.
2017.PubMed/NCBI
|
|
5
|
Giannelli G, Koudelkova P, Dituri F and
Mikulits W: Role of epithelial to mesenchymal transition in
hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Zijl F, Zulehner G, Petz M, Schneller
D, Kornauth C, Hau M, Machat G, Grubinger M, Huber H and Mikulits
W: Epithelial-mesenchymal transition in hepatocellular carcinoma.
Future Oncol. 5:1169–1179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bottoni P, Isgro MA and Scatena R: The
epithelialmesenchymal transition in cancer: A potential critical
topic for translational proteomic research. Expert Rev Proteomics
13–115–133. 2016. View Article : Google Scholar
|
|
8
|
Yang X, Lu P, Ishida Y, Kuziel WA, Fujii C
and Mukaida N: Attenuated liver tumor formation in the absence of
CCR2 with a concomitant reduction in the accumulation of hepatic
stellate cells, macrophages and neovascularization. Int J Cancer.
118:335–345. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang XW, Qin X, Qin CY, Yin YL, Chen Y
and Zhu HL: Expression of monocyte chemoattractant protein-1 and CC
chemokine receptor 2 in non-small cell lung cancer and its
significance. Cancer Immunol Immunother. 62:563–570. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hiratsuka S, Ishibashi S, Tomita T,
Watanabe A, Akashi-Takamura S, Murakami M, Kijima H, Miyake K,
Aburatani H and Maru Y: Primary tumours modulate innate immune
signalling to create pre-metastatic vascular hyperpermeability
foci. Nat Commu. 4:18532013. View Article : Google Scholar
|
|
11
|
Zhuang H, Cao G, Kou C and Liu T:
CCL2/CCR2 axis induces hepatocellular carcinoma invasion and
epithelial-mesenchymal transition in vitro through
activation of the hedgehog pathway. Oncol Rep. 39:21–30.
2018.PubMed/NCBI
|
|
12
|
Lim SY, Yuzhalin AE, Gordon-Weeks AN and
Muschel RJ: Targeting the CCL2-CCR2 signaling axis in cancer
metastasis. Oncotarget. 7:28697–28710. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dutta R and Mahato RI: Recent advances in
hepatocellular carcinoma therapy. Pharmacol Ther. 173:106–117.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong SHM, Fang CM, Chuah LH, Leong CO and
Ngai SC: E-cadherin: Its dysregulation in carcinogenesis and
clinical implications. Crit Rev Oncol Hematol. 121:11–22. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vu T and Datta PK: Regulation of EMT in
colorectal cancer: A Culprit in metastasis. Cancers. 9:E1712017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garg M: Epithelial plasticity and cancer
stem cells: Major mechanisms of cancer pathogenesis and therapy
resistance. World J Stem Cells. 9:118–126. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gaianigo N, Melisi D and Carbone C: EMT
and treatment resistance in pancreatic cancer. Cancers. 9:E1222017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qiu L, Tang Q, Li G and Chen K: Long
non-coding RNAs as biomarkers and therapeutic targets recent
insights into hepatocellular carcinoma. Life Sci. 191:273–282.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Giannelli G, Koudelkova P, Dituri F and
Mikulits W: Role of epithelial to mesenchymal transition in
hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu J, Li X, Guo X, Guo Q, Xiang C, Zhang
Z, Xing Y, Xi T and Zheng L: The CCR2 3′UTR functions as a
competing endogenous RNA to inhibit breast cancer metastasis. J
Cell Sci. 130:3399–3413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cai J, Wang M, Zhu M, Zhang Q, Zhang X,
Yan Y, Qian H and Xu W: N-methyl-N-nitro-N'-nitrosoguanidine
induces the expression of CCR2 in human gastric epithelial cells
promoting CCL2-mediated migration. Mol Med Rep. 13:1083–1090. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rao Q, Chen Y, Yeh CR, Ding J, Li L, Chang
C and Yeh S: Recruited mast cells in the tumor microenvironment
enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2
EMT/MMP9 signals. Oncotarget. 7:7842–7855. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moisan F, Francisco EB, Brozovic A, Duran
GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P and
Sikic BI: Enhancement of paclitaxel and carboplatin therapies by
CCL2 blockade in ovarian cancers. Mol Oncol. 8:1231–1239. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Izumi K, Fang LY, Mizokami A, Namiki M, Li
L, Lin WJ and Chang C: Targeting the androgen receptor with siRNA
promotes prostate cancer metastasis through enhanced macrophage
recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med.
5:1383–1401. 2013. View Article : Google Scholar : PubMed/NCBI
|
